Author: Healthcare Propulsion Staff

Amazon Pharmacy is collaborating with digital prescription platform eNAvvi to provide clinicians with real-time medication information and delivery options through its e-prescribing workflow. The partnership allows providers to see current pricing and stock for prescriptions, including cash pricing versus estimated insurance copays, and shows how quickly medications will reach patients, the companies said. The goal of the partnership is to support medication adherence and increase access for patients, especially for those in “pharmacy deserts.” eNavvi CEO Simon Chang said in a statement the collaboration “fundamentally changes what physicians can see and do at the moment of prescribing.”  “Transparent pricing, real-time…

Bodybuilders often share their main workouts on social media, demonstrating the heaviest reps of the day, but being a competitive flexer is a lifestyle that begins from the moment an athlete wakes up. To show what happens in the first half of his day, the British Nigerian bodybuilder, Yinka Majolagbe, who goes by the nickname, “Majonmuscle,” recently shared his morning routine online. Majonmuscle is readying for the 212-division final at the 2026 Olympia in Las Vegas, after qualifying at the IFBB EVLS Prague Pro, so there’s not a moment to waste. What is Yinka Majolagbe’s Morning Routine? Yinka Majolagbe starts his…

Recent research points to the potential utility of a familiar sounding foe-herpes virus-in the fight against cancer. The idea: the virus has evolved to commandeer cellular machinery in order activate signaling pathways inside cells and these strategies can be repurposed to bolster immunotherapy against diseases like cancer. T cells are front line defenders against pathogens, like viruses, and cancer because they can kill infected or malignant cells. Scientists have for years been trying different techniques to direct these immune cells to protect against disease. CAR-T therapy is one such example of prompting the body’s own immune system to attack certain…

Erica Schwartz, M.D., the latest nominee to lead the beleaguered Centers for Disease Control and Prevention (CDC), told lawmakers on Wednesday that she was committed to scientific integrity and transparency to restore trust in the country’s top public health agency. “As CDC director, my sacred responsibility is to provide the American people with public health guidance that is clear, honest and evidence-based. I will never betray the science,” Schwartz said during a confirmation hearing with the Senate Health, Education, Labor and Pensions Committee. Schwartz is President Donald Trump’s third CDC nominee in less than two years. The CDC has been…

A new study puts the spotlight on the rising burden of ischemic heart disease across Southeast Asia, East Asia and Oceania, and calls for localized, equity-focused interventions in these regions. The researchers identified region-specific, modifiable risk factors that influence the increasing prevalence of ischemic heart disease, such as toxic air pollution in East Asia and ultra-processed dietary dependence in Oceania. The study will be presented at the ACC Asia 2025 Together With SCS 36th Annual Scientific Meeting in Singapore. Ischemic heart disease (IHD) occurs when a narrowing of the arteries caused by plaque buildup reduces blood flow to the heart,…

Outpatient drug purchases under the 340B Drug Pricing Program crossed the $100 billion mark across 2025, a roughly 23% increase over the $81.4 billion of 2024, the Health Resources & Services Administration (HRSA) reported this week.  The tally is another escalation in scale for the controversial subsidy program, which critics say is being exploited by large nonprofit health systems to pad bottom lines. Purchases in the program, intended by Congress to support safety-net providers, had totaled $43.9 billion in 2021 and $16.2 billion in 2016, for reference.  In 2024, the purchases represented more than 16% of the country’s total drug…

New legislation introduced in the House by leaders of both parties’ doctors caucuses takes a crack at providers’ long-requested overhaul of annual physician payment adjustments. The Patients First Act (PDF of bill text) would eschew the year-to-year reimbursement formula established under 2015’s Medicare Access and CHIP Reauthorization Act (MACRA) to instead tie physician reimbursement to an inflationary measure. The formula would take the Medicare Economic Index and subtract one percentage point. The approach answers years of alarm from physicians and medical groups that the costs of running a practice have grown far faster than reimbursement. “We often talk about expanding…

Novo Nordisk’s new oral formulation of semaglutide 25 mg (Wegovy in a pill) produced a 16.6% average weight loss among adults with obesity, according to results from a newly published clinical study. The once-daily pill, developed as an alternative to the injectable version of Wegovy, helped one in three participants lose 20% or more of their body weight. In addition to significant weight reduction, those taking oral semaglutide 25 mg experienced improvements in daily physical function, including activities such as bending, walking, standing, and overall mobility, along with better cardiovascular risk profiles. Novo Nordisk has submitted the treatment to the…

Palliative care may help relieve symptoms and improve quality of life for people with cardiovascular disease and ensure that treatment is aligned with the patient’s personal beliefs and values throughout all stages of illness, whether they are hospitalized in a cardiac intensive care unit or receiving outpatient care, according to a new American Heart Association scientific statement published today in the Association’s flagship, peer-reviewed journal Circulation. The new scientific statement, “Palliative and End-of-Life Care During Critical Cardiovascular Illness,” suggests strategies to integrate palliative care principles into the management of patients with critical cardiovascular illness. Palliative care aims to improve quality…

New studies are revealing how medications that act on the glucagon-like peptide-1 (GLP-1) system influence brain networks tied to nausea, thirst, and reward-driven behaviors. GLP-1 drugs include commonly used treatments such as semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound). These findings will be featured at Neuroscience 2025, the Society for Neuroscience’s annual meeting and the largest global event for new research in brain science and health. Medications that work through the GLP-1 system are widely prescribed for type 2 diabetes and obesity. They imitate a natural hormone released in the digestive tract after eating and signal the…